

## **ANNUAL REPORT 2008-2009**

IATDM & CT Clinical Pharmacokinetics Committee

### **(A) Membership list (as per 2007):**

Alison Thomson, Betty Salustio, Daan Touw, Don LeGatt, Ehab El Desoky, Guillermo Bramugia, Kees Neef, Ken Ilett, Kimikazu Shinozaki, Li Wang, Michael Neely, Guido Paulo Caceres, Philip Patsalos, Pierre Marquet, Raman Venkat, Ray Morris, Roger Jelliffe, Sander Vinks, Shareen Cox, Zul Verjee, Reinier van Hest, Iona Macdonald.

### **(B) Report on activities between meetings:**

At the 2007 meeting in Nice, it was decided that the committee should make a proposal for a workshop to be held during the 2009 meeting in Montreal. After discussion the following topic was suggested and accepted: Personalised Medicine: How to develop pharmacokinetic and pharmacokinetic/pharmacodynamic models to aid in daily practice of model-based individualized drug treatment.

Suggested speakers are:

1. What is personalised medicine? How can PK/PD models aid in personalising drug treatment? Prof. dr. Alexander A Vinks.

2. Can models made by others be used in your situation? Dr. Daniel Touw

3. Implementation - What clinical software and support tools are available for routine PK/PD interpretation and guidance?

Dr. Jeff Barrett; 'Web-based Tools: Clinical evaluation of methotrexate and tacrolimus dashboards;

Dr. Franck Saint-Marcoux; Example of an in-house developed program dedicated to the dose adjustment of immunosuppressants;

Prof Roger W. Jelliffe; Pharmacometric Tools for Achieving Maximally Precise Drug Regimens

### **(C) Report on activities during meetings:**

#### **(C1) Presentations**

No presentations are reported.

#### **(C2) Publications of committee members:**

Neef C, Touw DJ, Stolk LM. Therapeutic Drug Monitoring in clinical research. *Pharm Med* 2008; 22: 235-244.

Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. *Clin Pharmacokinet.* 2009; 48: 71-88.

Lamont E, Seaton RA, Macpherson M, Semple L, Bell E, Thomson AH. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. *J Antimicrob Chemother.* 2009; 64: 181-187.

Thomson AH, Staatz, CE, Tobin C, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. *J Antimicrob Chemother.* 2009. 63 1050-1057.

Helgason K, Thomson A, Ferguson C. a review of vancomycin therapeutic drug monitoring recommendations in Scotland, *J Antimicrob Chemother.* 61:1398-1399, 2008.

MacDonald I, Staatz C, Jelliffe RW, Thomson AH. Evaluation and Comparison of Simple Multiple Model, Richer Data Multiple Model, and Sequential Interacting Multiple Model (IMM) Bayesian Analyses of Gentamicin and Vancomycin Data Collected From Patients Undergoing Cardiothoracic Surgery. *Ther Drug Monit* 2008 30: 67-74.

Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs – Best practice guidelines for therapeutic drug monitoring: A position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia* 2008; 49: 1239-1276.

Van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot RA. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. *Clin Pharmacokinet.* 2009;48(7):463-76.

#### **(D) List of objectives for the next year:**

To actively participate in national and international fora on therapeutic drug monitoring and clinical pharmacokinetics.

To develop ideas for committee activities during the 2011 conference.

Respectfully submitted,

Daniel J. Touw  
Chair, Clinical Pharmacokinetics committee  
September 22, 2009